Biogen, Alkermes MS drug bests Biogen’s soon-to-be-generic blockbuster in Phase III study
An analyst wrote that while the new drug, Vumerity, has a good chance of winning FDA approval later this year, it is uncertain whether the superior gastrointestinal tolerability it demonstrated will be enough to protect Tecfidera from generic competition.